Q2 EPS Forecast for Bristol Myers Squibb Cut by Analyst

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at William Blair lowered their Q2 2025 earnings per share estimates for Bristol Myers Squibb in a research note issued to investors on Monday, July 14th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $1.03 per share for the quarter, down from their prior estimate of $1.52. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

BMY has been the subject of a number of other reports. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Jefferies Financial Group lowered their target price on Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research note on Wednesday, April 23rd. Morgan Stanley reduced their price target on Bristol Myers Squibb from $36.00 to $34.00 and set an “underweight” rating for the company in a research report on Thursday, July 10th. Finally, Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $57.69.

Bristol Myers Squibb Stock Up 1.6%

NYSE:BMY opened at $47.16 on Wednesday. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The company’s fifty day moving average price is $47.42 and its 200-day moving average price is $53.06. Bristol Myers Squibb has a 1-year low of $41.20 and a 1-year high of $63.33. The firm has a market capitalization of $95.98 billion, a P/E ratio of 17.66, a PEG ratio of 2.39 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the company earned ($4.40) EPS. Bristol Myers Squibb’s quarterly revenue was down 5.6% on a year-over-year basis.

Institutional Trading of Bristol Myers Squibb

Several institutional investors have recently modified their holdings of BMY. Pinney & Scofield Inc. purchased a new position in Bristol Myers Squibb in the 4th quarter valued at about $25,000. Park Square Financial Group LLC purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $26,000. Global Wealth Strategies & Associates raised its holdings in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 275 shares during the last quarter. Transce3nd LLC purchased a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Bristol Myers Squibb in the first quarter worth approximately $31,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.26%. Bristol Myers Squibb’s dividend payout ratio is currently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.